For example, Birinapant, a mimetic of the second mitochondrial-derived activator of caspases (SMAC), was able to upregulate MHC-I in preclinical melanoma models, which resulted in cancer cell sensitization to CD8+ T cell-dependent cytotoxicity and enhanced immune checkpoint blockade efficacy [107]. Here, CD8A is linked to melanoma.